T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (68)	3/24/2000 8:11:00 AM
From: Jim Oravetz	of 2243

Pharmacopeia (PCOP) 55 13/16 +3 13/16: So you're a little nervous about buying stock in the volatile biotech industry... That's understandable... The group has been under pressure in recent weeks and it is often difficult to get a grasp of what these companies are doing, and when they will become profitable... But even if you don't know the difference between Phase I and Phase II trials, one thing is pretty clear - the biotech industry is in the early stages of a major upturn... The pipeline of new drugs/therapies is larger today that at any time in history... Favorable demographics and a positive regulatory environment suggest that development will remain brisk for years to come... If true than one way to play the sector, is to invest in companies that provide the technology which helps biotech and pharmaceutical companies speed up the discovery of new drugs/therapies... PCOP is one such company... Its offers products and services to accelerate drug discovery and chemicals development integrating three platform technologies: small molecule combinatorial chemistry, high-throughput screening, and simulations software... Basically it functions as an outsourcing firm for the biotech/drug industries... Not surprisingly, its fundamentals are much better than many of the strict R&D biotech outfits... PCOP is projected to earn $0.44 in FY00 and $0.77 in FY01... Five year growth rate is 50%... Company has solid financials and strong management team... So if the recent price swings and lack of profitability unnerve you, and the all the talk about genomics confuses you, then you might want to consider PCOP as a way to participate in the sector's exciting future... Barring a complete meltdown in the sector, PCOP should rebound to the 75-80 range over next 6- to 12-months. -- RW Source:Briefing.com 3/24 Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next